Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Multiple Myeloma

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Regulators limited the relaunch to one regimen because safety concerns offset strong efficacy data.

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit